Drugs for Alzheimer's disease: are they effective?

Disclosure. Dr. Casey reports that he serves on the speaker’s bureau for Pfizer. Dr. Antimisiaris and Dr. O’Brien report that they have no financial or commercial relationships in regard to this article.

[1]  Kevin Weiss,et al.  Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. , 2017, Annals of internal medicine.

[2]  Brian Hutton,et al.  Does analysis using “last observation carried forward” introduce bias in dementia research? , 2008, Canadian Medical Association Journal.

[3]  R. Frierson.  Dementia, Delirium, and Other Cognitive Disorders , 2008 .

[4]  T. Finucane,et al.  Results, Rhetoric, and Randomized Trials: The Case of Donepezil , 2008, Journal of the American Geriatrics Society.

[5]  Bradley R. Johnson,et al.  American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. , 2007, The American journal of psychiatry.

[6]  Martin Knapp,et al.  Donepezil for the treatment of agitation in Alzheimer's disease. , 2007, The New England journal of medicine.

[7]  Claire Mount,et al.  Alzheimer disease: progress or profit? , 2006, Nature Medicine.

[8]  L. Schneider,et al.  Memantine for dementia. , 2006, The Cochrane database of systematic reviews.

[9]  J. Birks,et al.  Cholinesterase inhibitors for Alzheimer's disease. , 2006 .

[10]  D. Wilkinson,et al.  The safety and tolerability of donepezil in patients with Alzheimer's disease. , 2004, British journal of clinical pharmacology.

[11]  W. Kukull,et al.  Survival after Initial Diagnosis of Alzheimer Disease , 2004, Annals of Internal Medicine.

[12]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[13]  D. Geldmacher,et al.  Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease , 2003, Journal of the American Geriatrics Society.

[14]  J. Orgogozo,et al.  Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300) , 2002, Stroke.

[15]  R. Taylor,et al.  NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE (NICE) , 2002, International Journal of Technology Assessment in Health Care.

[16]  J. Noble,et al.  Drugs for Alzheimer's disease , 2001, BMJ : British Medical Journal.

[17]  B. Winblad,et al.  Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine) , 1999, International journal of geriatric psychiatry.

[18]  D. Knopman,et al.  The Clinician Interview‐ Based Impression (CIBI) , 1994, Neurology.

[19]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[20]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[21]  J. Vernon,et al.  Alzheimer's Disease and Cost-effectiveness Analyses: Ensuring Good Value for Money? , 2010 .